| 摘要: |
| ［摘要］ 微小病变（MCD）被认为是一种足突细胞疾病，临床表现主要以肾病综合征为主。利妥昔单抗（RTX）是一种人/鼠嵌合型单克隆抗体，目前应用在治疗免疫介导的肾脏疾病中，并取得了一定的疗效。近年来RTX用于治疗MCD患者的研究取得了一定的进展，丰富了MCD患者的治疗方案，该文就目前RTX在MCD患者中的应用进展作一综述。 |
| 关键词: 利妥昔单抗 微小病变 肾病综合征 |
| DOI：10.3969/j.issn.1674-3806.2021.03.20 |
| 分类号:R 692 |
| 基金项目:国家临床重点专科能力建设项目（编号：2019-QTL-013） |
|
| Application progress of rituximab in minimal change disease |
|
TIAN Jing-wei, ZHUO li
|
|
Department of Nephrology, Beijing Sixth Hospital, Beijing 100007, China
|
| Abstract: |
| ［Abstract］ Minimal change disease(MCD) is considered to be a kind of podocytopathy, with a predominant clinical manifestation of nephrotic syndrome. Rituximab(RTX), a human-mouse chimeric monoclonal antibody, is currently administered in the treatment of immune-mediated renal diseases, and has achieved certain curative effect. In recent years, the research of RTX in the treatment of MCD patients has made some progress, which enriches the treatment options of MCD patients. In this paper, we review the current application progress of RTX in MCD patients. |
| Key words: Rituximab(RTX) Minimal change disease(MCD) Nephrotic syndrome(NS) |
